Ascendis Pharma A/S
Veridion Score
Composite trend over time
Why is ASND moving today?
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ASND.
ASND insider activity
Ascendis Pharma A/S
2 insiders bought in the last 90 days
Net selling: -$4.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-06-02 | SMITH SCOTT THOMAS | Insider | buy | $219.00 | 100 | 4,367 | $22K | SEC Form 4 |
| 2026-06-01 | 2026-05-29 | SMITH SCOTT THOMAS | Insider | buy | $223.32 | 250 | 4,267 | $56K | SEC Form 4 |
| 2026-06-01 | 2026-05-29 | BIENAIME JEAN JACQUES | Insider | buy | $223.50 | 100 | 900 | $22K | SEC Form 4 |
| 2026-06-01 | 2026-05-29 | BIENAIME JEAN JACQUES | Insider | buy | $222.30 | 200 | 800 | $44K | SEC Form 4 |
| 2026-06-01 | 2026-05-29 | BIENAIME JEAN JACQUES | Insider | buy | $223.76 | 200 | 600 | $45K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 3 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moASND contract awards, year to date.
Public federal awards linked to this ticker.
ASND lobbying filings, year to date.
Registered lobbying filings matched to Ascendis Pharma A/S.